Comparing Phase II NASH data from Viking and Madrigal
Viking’s VK2809 appears to reduce liver fat as well as Madrigal’s resmetirom, which went on to show efficacy in Phase III
If liver fat reduction in Phase II is predictive of Phase III performance in NASH, then Viking’s top-line findings, reported Tuesday, could suggest it is on track to be as effective in Phase III as Madrigal’s resmetirom. The data sent Viking’s shares up 12% to $24.65.
Both companies’ small molecules are THRB agonists. ...